



Continuing a Legacy of Innovation

As a leading specialty pharmaceutical company, Salix has been on the cutting edge in treating and preventing gastrointestinal (GI) disorders for over 25 years. Since that time, we have been fueled by our primary purpose of improving the daily lives of millions of Americans affected by GI health conditions.

Founded in 1989, our Salix commitment to inflammatory bowel disease (IBD) began with the development of our 1st product—an innovative pro-drug designed to treat active, mild to moderate ulcerative colitis.

Over the years, we've continued to make innovations in the available therapeutic options for the IBD patient. Today, our innovation has evolved to not only encompass IBD, but also to include more than 20 additional products developed for irritable bowel syndrome with diarrhea (IBS-D), hepatic encephalopathy, bowel prep, opioid-induced constipation, and other GI disorders.

We believe that building relationships is at the heart of our mission, so we strive to be more and do more for the patients and healthcare providers we serve. In a constant effort to advance our knowledge and capabilities, we continuously invest in research and development, while also welcoming opportunities to license and add beneficial products to our portfolio.



"...we improve lives through our healthcare products..."

Currently, we have several exciting GI treatments in various stages of development and approval, which we believe will significantly benefit the patients of tomorrow. It is also our pleasure to share that we are exploring several new therapeutic areas where we can further help the GI patient.

With new treatments come new responsibilities, and we plan on keeping the spirit of progress and integrity alive to boldly answer the call of the future in support of the GI community.

At Salix, we improve lives through our healthcare products by arming healthcare providers with the most innovative and life-changing solutions in gastroenterology. With this primary mission and vision in mind, we will stay committed to being your trusted healthcare partner.

With great respect,

Mark C. McKenna
Senior Vice President and General Manager
Salix Pharmaceuticals

You can learn more about our products at salix.com.



SAL.0044.USA.16